U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
149124
Name Type Language
GSK-3196165
Preferred Name English
OTILIMAB
USAN   INN  
Official Name English
OTILIMAB [JAN]
Common Name English
GSK3196165
Code English
otilimab [INN]
Common Name English
OTILIMAB [USAN]
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR) (HUMAN MONOCLONAL GSK3196165 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL GSK3196165 .LAMBDA.-CHAIN, DIMER
Systematic Name English
IMMUNOGLOBULIN G1-LAMBDA, ANTI-(HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF, CSF))HUMAN MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN (1-447) (HUMAN VH (HOMO SAPIENS IGHV3-NL1*01 (88%) (IGHD)-IGHJ1*01) (8.10.8) (1-117) -HOMO SAPIENS IGHG1*03
Systematic Name English
Otilimab [WHO-DD]
Common Name English
MOR103
Code English
MOR-103
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 439314
Created by admin on Tue Apr 01 21:49:26 GMT 2025 , Edited by admin on Tue Apr 01 21:49:26 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C170271
Created by admin on Tue Apr 01 21:49:26 GMT 2025 , Edited by admin on Tue Apr 01 21:49:26 GMT 2025
PRIMARY
SMS_ID
100000183546
Created by admin on Tue Apr 01 21:49:26 GMT 2025 , Edited by admin on Tue Apr 01 21:49:26 GMT 2025
PRIMARY
FDA UNII
Y8127R3VCH
Created by admin on Tue Apr 01 21:49:26 GMT 2025 , Edited by admin on Tue Apr 01 21:49:26 GMT 2025
PRIMARY
CAS
1638332-55-4
Created by admin on Tue Apr 01 21:49:26 GMT 2025 , Edited by admin on Tue Apr 01 21:49:26 GMT 2025
PRIMARY
USAN
EF-39
Created by admin on Tue Apr 01 21:49:26 GMT 2025 , Edited by admin on Tue Apr 01 21:49:26 GMT 2025
PRIMARY
INN
10783
Created by admin on Tue Apr 01 21:49:26 GMT 2025 , Edited by admin on Tue Apr 01 21:49:26 GMT 2025
PRIMARY
DRUG BANK
DB06303
Created by admin on Tue Apr 01 21:49:26 GMT 2025 , Edited by admin on Tue Apr 01 21:49:26 GMT 2025
PRIMARY
WIKIPEDIA
Otilimab
Created by admin on Tue Apr 01 21:49:26 GMT 2025 , Edited by admin on Tue Apr 01 21:49:26 GMT 2025
PRIMARY
ACTIVE MOIETY
OTILIMAB
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966